Lisata Therapeutics Files 8-K
Ticker: LSTA · Form: 8-K · Filed: Jul 15, 2025 · CIK: 320017
Sentiment: neutral
Topics: corporate-event, filing, pharmaceutical
Related Tickers: CLBS
TL;DR
Lisata Therapeutics filed an 8-K on 7/15/25. Check it for updates.
AI Summary
Lisata Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting on other events and financial statements. The company, formerly known as Caladrius Biosciences, Inc., is incorporated in Delaware and has its principal executive offices in Basking Ridge, NJ.
Why It Matters
This filing provides an update on the company's corporate events and financial status, which is crucial for investors to understand the company's current standing.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant corporate events or financial updates without immediate market-moving news.
Key Numbers
- 001-33650 — SEC File Number (Identifies the company's filing with the SEC)
- 22-2343568 — EIN (Employer Identification Number for tax purposes)
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Registrant
- CALADRIUS BIOSCIENCES, INC. (company) — Former company name
- NeoStem, Inc. (company) — Former company name
- July 15, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Basking Ridge, NJ (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the provided text snippet.
What is the significance of the former company names listed?
The former company names (Caladrius Biosciences, Inc. and NeoStem, Inc.) indicate historical changes in the company's identity or structure prior to its current name, Lisata Therapeutics, Inc.
When was the company incorporated?
The company was incorporated in Delaware, as indicated by the filing.
What is the company's primary business sector?
The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]', indicating its focus on pharmaceutical products.
What is the address of the company's principal executive offices?
The principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 15, 2025 regarding LISATA THERAPEUTICS, INC. (LSTA).